Evidence map›Paper›PMID 30613352›Full record

ArticleOncotarget2018

Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase

Mariya Shapovalova, Julia Davydova, Christine Henzler, Mark Daniel, Scott M Dehm, Christopher A Warlick, Aaron M LeBeau

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mariya ShapovalovaDepartment of Pharmacology, University of Minnesota, Minneapolis 55455, MN, USA.
Julia DavydovaDepartment of Surgery, University of Minnesota, Minneapolis 55455, MN, USA.
Christine HenzlerDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455, MN, USA.
Mark DanielDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis 55455, MN, USA.
Scott M DehmDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455, MN, USA.
Christopher A WarlickDepartment of Urology, University of Minnesota, Minneapolis 55455, MN, USA.
Aaron M LeBeauDepartment of Pharmacology, University of Minnesota, Minneapolis 55455, MN, USA.
University of Minnesota · US

Funding

AR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9M
Novel Theranostics for Pancreatic CancerR01CA174861 · NCI · UNIVERSITY OF MINNESOTA · PI DAVYDOVA, JULIA · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA174777NCI NIH HHS R01 CA174861
6 · The paper itself

Abstract

The metabolic protein alpha-methylacyl-CoA racemase (AMACR) is significantly overexpressed in prostate cancer compared to the normal prostate and other non-malignant tissue. Though an attractive target, there are no reports in the literature on leveraging the expression of AMACR for the molecular imaging of prostate cancer. Here, we used a molecular-genetic imaging strategy to exploit the transcriptional specificity of the AMACR promoter for the

Indexed as

adenovirusmolecular imagingprostate cancerα-methylacyl-CoA racemase

Identifiers

PMID30613352
PMCPMC6291171
OpenAlexW4238033916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.